Literature DB >> 29296756

Implications of the US Food and Drug Administration draft guidance for mitigating septic reactions from platelet transfusions.

Bruce S Sachais1, Sarai Paradiso1, Donna Strauss1, Beth H Shaz1.   

Abstract

Year:  2017        PMID： 29296756      PMCID： PMC5728328          DOI： 10.1182/bloodadvances.2017008334

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  22 in total

1.  Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance.

Authors:  Hong Hong; Wenbin Xiao; Hillard M Lazarus; Caryn E Good; Robert W Maitta; Michael R Jacobs
Journal:  Blood       Date:  2015-11-23       Impact factor: 22.113

2.  Refrigerated Platelets for the Treatment of Acute Bleeding: A Review of the Literature and Reexamination of Current Standards: Reply.

Authors:  Heather F Pidcoke; Andrew P Cap
Journal:  Shock       Date:  2015-03       Impact factor: 3.454

3.  Detection of bacterial contamination in apheresis platelets: is apheresis technology a factor?

Authors:  Marjorie Bravo; Beth H Shaz; Hany Kamel; Sandra Vanderpool; Peter Tomasulo; Brian Custer; Mary Townsend
Journal:  Transfusion       Date:  2015-04-09       Impact factor: 3.157

4.  Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.

Authors:  Paolo Rebulla; Stefania Vaglio; Francesco Beccaria; Maurizio Bonfichi; Angelo Carella; Federico Chiurazzi; Serelina Coluzzi; Agostino Cortelezzi; Giorgio Gandini; Gabriella Girelli; Maria Graf; Paola Isernia; Giuseppe Marano; Maurizio Marconi; Rachele Montemezzi; Barbara Olivero; Marianna Rinaldi; Laura Salvaneschi; Nicola Scarpato; Paolo Strada; Silvano Milani; Giuliano Grazzini
Journal:  Transfusion       Date:  2017-02-24       Impact factor: 3.157

5.  Anti-D alloimmunization propensity cannot be determined without information on D antigen exposure.

Authors:  Mark H Yazer; Darrell J Triulzi
Journal:  Transfusion       Date:  2012-09       Impact factor: 3.157

6.  How do we implement Day 6 and Day 7 platelets at a hospital-based transfusion service?

Authors:  Nancy M Dunbar; Larry J Dumont; Zbigniew M Szczepiorkowski
Journal:  Transfusion       Date:  2016-03-28       Impact factor: 3.157

7.  Safety and efficacy of cryopreserved autologous platelet concentrates in HLA-alloimmunized patients with hematologic malignancies.

Authors:  Bernhard Gerber; Lorenzo Alberio; Sophie Rochat; Frank Stenner; Markus G Manz; Andy Buser; Urs Schanz; Georg Stussi
Journal:  Transfusion       Date:  2016-06-24       Impact factor: 3.157

8.  A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.

Authors:  Miguel Lozano; Folke Knutson; René Tardivel; Joan Cid; Rosa Maria Maymó; Helena Löf; Huw Roddie; Jane Pelly; Anthony Docherty; Claire Sherman; Lily Lin; Meisa Propst; Laurence Corash; Chris Prowse
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

9.  The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.

Authors:  Darrell J Triulzi; Susan F Assmann; Ronald G Strauss; P M Ness; John R Hess; Richard M Kaufman; Suzanne Granger; Sherrill J Slichter
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

10.  A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial.

Authors:  Paula F Ypma; Pieter F van der Meer; Nancy M Heddle; Joost A van Hilten; Theo Stijnen; Rutger A Middelburg; Tor Hervig; Johanna G van der Bom; Anneke Brand; Jean-Louis H Kerkhoffs
Journal:  BMJ Open       Date:  2016-01-27       Impact factor: 2.692
View more
  2 in total

1.  How do you… decide which platelet bacterial risk mitigation strategy to select for your hospital-based transfusion service?

Authors:  Wen Lu; Meghan Delaney; Willy A Flegel; Paul Ness; Nora Ratcliffe; Darrell J Triulzi; Mark H Yazer; Alyssa Ziman; Nancy M Dunbar
Journal:  Transfusion       Date:  2020-02-06       Impact factor: 3.337

2.  The argument(s) for lowering the US minimum required content of apheresis platelet components.

Authors:  Richard J Benjamin; Louis Katz; Richard R Gammon; Susan L Stramer; Eva Quinley
Journal:  Transfusion       Date:  2018-11-21       Impact factor: 3.157
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.